Medtronic (NYSE:MDT) said today it won FDA approval for its Intellis implantable spinal cord stimulation system and launched it in the US.
The Fridley, Minn.-based company touted the newly revised system as the world’s smallest, and said that the new unit was designed to improve battery performance and standardize guidance and balancing of high-dose and low-dose therapy settings.
“Drawing upon our 40-year legacy in SCS, the launch of the Intellis platform isn’t just about a new device, but about combining cutting edge hardware with optimal therapy through the Evolve workflow to enable personalized, long-term pain relief.